MABC985
Anti-TRAF4 Antibody, clone 5MLN-2H1
ascites fluid, clone 5MLN-2H1, from mouse
Synonyme(s) :
TNF receptor-associated factor 4, Cysteine-rich domain associated with RING and Traf domains protein 1, Metastatic lymph node gene 62 protein, MLN 62, RING finger protein 83
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
ascites fluid
Type de produit anticorps
primary antibodies
Clone
5MLN-2H1, monoclonal
Espèces réactives
mouse, human
Réactivité de l'espèce (prédite par homologie)
rat (based on 100% sequence homology)
Technique(s)
immunocytochemistry: suitable
immunohistochemistry: suitable
western blot: suitable
Isotype
IgG1
Numéro d'accès NCBI
Numéro d'accès UniProt
Conditions d'expédition
wet ice
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... TRAF4(9618)
Description générale
TNF receptor-associated factor 4 (TRAF4), also known as Cysteine-rich domain associated with RING and Traf domains protein 1 (CART1), Metastatic lymph node gene 62 protein (MLN 62), and RING finger protein 83 (RNF83), is an adapter protein and signal transducer that links members of the TNF family to different signaling pathways. As such TRAF4 plays a role in the activation of the NF-kappa- and JNK signaling as well as a player in apoptosis and cell survival pathways. In development, TRAF4 is necessary for proper skeleton development and lung development. TRAF4 is localized in the perinuclear region of the cell as well as other locations including cell junctions where it is associated with various cytoskeletal elements. TRAF4 is expressed in the epithelial cells of thymus, respiratory tract, salivary gland, and esophagus. TRAF4 expression is regulated via the ubiquitin proteasome system and is a polyubiquitin target protein.
Spécificité
This antibody detects TRAF4 and is cited in publications as both clone 5MLN-2H1 and clone 2H1.
Immunogène
Linear peptide corresponding to Human TRAF4.
Application
Imunnohistochemistry Analysis: A representative lot of this antibody detected TRAF4 in multiple human cancer tissues (Camilleri-Broet. S., et al. (2007) Oncogene. 26:142-147).
Imunnohistochemistry Analysis: A representative lot of this antibody detected TRAF4 in Breast cancer tissue (Kedinger, V., et. al. (2008) PLoS ONE. 3(10):e3518).
Immunocytochemistry Analysis: A representative lot of this antibody detected TRAF4 in MCF-10A cells and tranfected HeLa cells (Kedinger, V., et. al. (2008) PLoS ONE. 3(10):e3518).
Imunnohistochemistry Analysis: A representative lot of this antibody detected TRAF4 in Breast cancer tissue (Kedinger, V., et. al. (2008) PLoS ONE. 3(10):e3518).
Immunocytochemistry Analysis: A representative lot of this antibody detected TRAF4 in MCF-10A cells and tranfected HeLa cells (Kedinger, V., et. al. (2008) PLoS ONE. 3(10):e3518).
Research Category
Apoptosis & Cancer
Apoptosis & Cancer
Research Sub Category
Tumor Markers
Tumor Markers
This Anti-TRAF4 Antibody, clone 5MLN-2H1 is validated for use in Western Blotting and Immunohistochemistry and Immunocytochemistry for the detection of TRAF4.
Qualité
Evaluated by Western Blotting in HeLa cell lysate.
Western Blotting Analysis: A 1:1000 dilution of this antibody detected TRAF4 in 10 µg of HeLa cell lysate.
Western Blotting Analysis: A 1:1000 dilution of this antibody detected TRAF4 in 10 µg of HeLa cell lysate.
Description de la cible
~53 kDa observed
Forme physique
Mouse monoclonal IgG1 ascites without preservatives.
Unpurified
Stockage et stabilité
Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Autres remarques
Concentration: Please refer to lot specific datasheet.
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 1
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Impaired neural tube closure, axial skeleton malformations, and tracheal ring disruption in TRAF4-deficient mice.
Regnier, CH; Masson, R; Kedinger, V; Textoris, J; Stoll, I; Chenard, MP; Dierich et al.
Proceedings of the National Academy of Sciences of the USA null
Tumor necrosis factor receptor-associated factor 4 is a dynamic tight junction-related shuttle protein involved in epithelium homeostasis.
Kedinger, V; Alpy, F; Baguet, A; Polette, M; Stoll, I; Chenard, MP; Tomasetto, C; Rio, MC
Testing null
TRAF4 overexpression is a common characteristic of human carcinomas.
Camilleri-Broet, S; Cremer, I; Marmey, B; Comperat, E; Viguie, F; Audouin, J; Rio et al.
Oncogene null
Xin Dong et al.
Cell death & disease, 14(2), 102-102 (2023-02-11)
The E3 ligase TNF receptor-associated factor 4 (TRAF4) is upregulated and closely associated with tumorigenesis and the progression of multiple human malignancies. However, its effect on radiosensitivity in colorectal cancer (CRC) has not been elucidated. The present study found that
Xinfang Yu et al.
Journal of hematology & oncology, 13(1), 40-40 (2020-05-03)
Aberrant activation of DNA damage response (DDR) is a major cause of chemoresistance in colorectal cancer (CRC). CHK1 is upregulated in CRC and contributes to therapeutic resistance. We investigated the upstream signaling pathways governing CHK1 activation in CRC. We identified
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique